Your session is about to expire
← Back to Search
Study Summary
This trial is testing the safety of AGN-151586, an investigational product being developed for the treatment of glabellar lines (GL). 880 adult participants with moderate to severe GL will receive 5 intramuscular AGN-151586 injections on Day 1, and may receive up to 2 additional cycles of treatment during the study.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 2 trial • 198 Patients • NCT04096326Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there risks involved with AGN-151586?
"AGN-151586 has been given a 3 for safety. This is based on the fact that it is a Phase 3 trial, so while there is some data to support efficacy, there are also multiple rounds of data to support safety."
Are there other places in town where this research project is taking place?
"There are 43 clinical trial sites recruiting patients for this study, including the Northwest Dermatology Institute in Portland, Advanced Research Associates in Glendale, and Skin Research Institute LLC in Coral Gables."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger